Top

Published in:

18-01-2022 | Colorectal Cancer | Original Article

Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center

Authors: Ashini H. Shah, Amisha J. Gami, Neetal H. Desai, Jahnavi S. Gandhi, Priti P. Trivedi

Published in: Indian Journal of Surgical Oncology | Issue 3/2022

Abstract

Colorectal carcinoma (CRC) is the third most common cancer worldwide. Along with many established prognostic factors, tumor budding is emerging as a valuable marker of prognosis. Tumor budding is not yet universally reported but it has recently been suggested in guidelines by ITBCC (International Tumor Budding Consensus Conference). Our aim is to study prognostic implications of tumor budding in CRC. Hundred cases of primary CRC specimens were retrospectively studied from January, 2016, to February, 2017. Tumor bud count and other histopathological parameters were evaluated from hematoxyline and eosin (H & E) stained slides. Survival analysis was done using Cox proportional hazards model. Association of tumor budding and cancer-specific survival was found to be statistically significant (P = 0.018 for average tumor budding and P = 0.035 for highest tumor budding) Tumor budding was found to be significantly associated with other clinicopathological parameters such as T stage, N stage, TNM stage, and lymphovascular invasion with p value < 0.05. Tumor budding is a valuable prognostic indictor for primary CRC and also significantly associated with other prognostic parameters. It should be reported routinely as a guide to prognosis and further management of patients.

Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89–103. https://doi.org/10.5114/pg.2018.81072CrossRefPubMedPubMedCentral

De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M (2014) Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol 20(41):15049–15059. https://doi.org/10.3748/wjg.v20.i41.15049CrossRefPubMedPubMedCentral

Poornakala S, Prema NS (2019) A study of morphological prognostic factors in colorectal cancer and survival analysis. Indian J Pathol Microbiol 62:36–42CrossRef

Lugli A, Kirsch R, Ajioka Y et al (2017) Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 30(9):1299–1311. https://doi.org/10.1038/modpathol.2017.46CrossRefPubMed

Prall F, Nizze H, Barten M (2005) Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 47:17–24CrossRef

Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I (2002) Tumourbudding’as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40:127–132CrossRef

Imai T (1954) The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi 45:13–43

Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M (1989) An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63:539–543CrossRef

Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H (2006) Tumor budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody Cam 5.2. Br J Cancer 94:293–298CrossRef

10.

Losi L, Ponti G, Grego DC, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP (2006) Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 202:663–670CrossRef

11.

Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS (2007) Tumor budding as a prognostic marker in stage III rectal carcinoma. Int J Colorectal Dis 22:863–868CrossRef

12.

Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, Watanabe M (2008) Tumor budding at invasive margins and outcome in colorectal cancer. Colorectal Dis 10:41–47PubMed

13.

Ishikawa Y, Akishima-Fukasawa Y, Ito K et al (2008) Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer 112(4):924–933CrossRef

14.

Kye BH, Jung JH, Kim HJ, Kang SG, Cho HM, Kim JG (2012) Tumor budding as a risk factor of lymph node metastasis in submucosal invasive T1 colorectal carcinoma: a retrospective study. BMC Surg 12:16CrossRef

15.

Okuyama T, Nakamura T, Yamaguchi M (2003) Budding is useful to select highrisk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 46(10):1400–1406CrossRef

16.

Horcic M, Koelzer VH, Karamitopoulou E et al (2013) Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol 44(5):697–705CrossRef

17.

Betge J, Kornprat P, Pollheimer MJ et al (2012) Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol 19(12):3706–3712CrossRef

18.

Loughrey M, Quirke P, Shepherd NA (2018) Standards and datasets for reporting cancers. Dataset for histopathological reporting of colorectal cancer. https://www.rcpath.org/uploads/assets/uploaded/0d5e22ce-be66–474c-ba3097adae84121d. Assessed 23 Feb 2019

19.

College of American Pathologists (2020) Protocol for examination of resection specimens from patients with primary carcinoma of the colon and rectum. Version: ColoRectum 4.1.0.0. CAP

20.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR et al (eds) (2017) AJCC Cancer Staging Manual (8th edition). Springer International Publishing, American Joint Commission on Cancer

21.

Fuchs TL, Sioson L, Sheen A, Jafari-Nejad K, Renaud CJ, Andrici J, Ahadi M, Chou A, Gill AJ (2020) Assessment of tumor-infiltrating lymphocytes using International TILs Working Group (ITWG) system is a strong predictor of overall survival in colorectal carcinoma. Am J Surg Pathol 44(4):536–544. https://doi.org/10.1097/PAS.0000000000001409CrossRefPubMed

22.

van Wyk HC, Roseweir A, Alexander P et al (2019) The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann Surg Oncol 26:4397–4404. https://doi.org/10.1245/s10434-019-07931-6CrossRefPubMedPubMedCentral

23.

Bektas SS, Mamak GI, Ciris IM, Bozkurt KK, Kapucuoglu N (2012) Tumor budding in colorectal carcinomas. Turk J Pathol 28(1):61. https://doi.org/10.5146/tjpath.2012.01099CrossRef

24.

Koelzer VH, Zlobec I, Lugli A (2016) Tumor budding in colorectal cancer–ready for diagnostic practice? Hum Pathol 47(1):4–19. https://doi.org/10.1016/j.humpath.2015.08.007CrossRefPubMed

25.

Cho S-J, Kakar S (2018) Tumor budding in colorectal carcinoma: translating a morphologic score into clinically meaningful results. Arch Pathol Lab Med 142(8):952–957. https://doi.org/10.5858/arpa.2018-0082-raCrossRefPubMed

26.

Zlobec I, Berger MD, Lugli A (2020) Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer 123:700–708. https://doi.org/10.1038/s41416-020-0954-zCrossRefPubMedPubMedCentral

27.

Deb B, Jacob SE (2019) Predictive power of tumour budding for lymph node metastasis in colorectal carcinomas: a retrospective study. Indian J Med Res 150(6):635–639. https://doi.org/10.4103/ijmr.IJMR_1268_17CrossRefPubMedPubMedCentral

28.

Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, Sheahan K (2016) Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 115(7):831–840. https://doi.org/10.1038/bjc.2016.274CrossRefPubMedPubMedCentral

29.

Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A (2010) Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 16(38):4823–4831. https://doi.org/10.3748/wjg.v16.i38.4823CrossRefPubMedPubMedCentral

30.

Mehta A, Goswami M, Sinha R, Dogra A (2018) Histopathological significance and prognostic impact of tumor budding in colorectal cancer. Asian Pac J Cancer Prev 19(9):2447–2453. https://doi.org/10.22034/APJCP.2018.19.9.2447CrossRefPubMedPubMedCentral

31.

El-Gendi S, Al-Gendi A (2011) Assessment of tumor budding in colorectal carcinoma: correlation with b-catenin nuclear expression. J Egypt Natl Canc Inst. 23:1–9 [PubMed] [Google Scholar]CrossRef

32.

Dawson H, Christe L, Eichmann M, Reinhard S, Zlobec I, Blank A, Lugli A (2020) Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score. Histopathology 76:572–580. https://doi.org/10.1111/his.14006CrossRefPubMed

33.

Lee H, Sha D, Foster N, Shi Q, Alberts S, Smyrk T, Sinicrope F (2020) Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol 31(4):487–494. https://doi.org/10.1016/j.annonc.2020.01.011CrossRefPubMed

34.

Yun SO, Cho YB, Lee WY, Kim HC, Yun SH, Park YA, Huh JW (2017) Clinical significance of signet-ring-cell colorectal cancer as a prognostic factor. Ann Coloproctol 33(6):232–238. https://doi.org/10.3393/ac.2017.33.6.232CrossRefPubMedPubMedCentral

35.

Satoh K, Nimura S, Aoki M, Hamasaki M, Koga K, Iwasaki H, Yamashita Y, Kataoka H, Nabeshima K (2014) Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci 105(11):1487–1495. https://doi.org/10.1111/cas.12530CrossRefPubMedPubMedCentral

36.

Hacking S, Sajjan S, Angert M et al (2019) Tumor budding in colorectal carcinoma showing a paradoxical mitotic index (via PHH3) with possible association to the tumor stromal microenvironment [published online ahead of print, 2019 Sep 18]. Appl Immunohistochem Mol Morphol. https://doi.org/10.1097/PAI.0000000000000805

Title: Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center
Authors: Ashini H. Shah
Amisha J. Gami
Neetal H. Desai
Jahnavi S. Gandhi
Priti P. Trivedi
Publication date: 18-01-2022
Publisher: Springer India
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Indian Journal of Surgical Oncology / Issue 3/2022
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-022-01498-7

At a glance: The STEP trials

Springer Medicine

Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Breast Cancer—Comprehensive Management

Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation

Gastrosplenic Fistula: a Systematic Review

Post-treatment Residual Clinicopathological Outcomes in Testicular Germ Cell Tumours

Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study

Cutaneous Ureterostomy or Ileal Conduit Urinary Diversion: Can We Spare the Bowel Following Radical Cystectomy in Patients with Solitary Functioning Kidney?